Paclitaxel is a standard of care for patients with primary cutaneous angiosarcoma of the scalp and face. However, no standard second-line treatment for paclitaxel-resistant patients has ever been established. | A single-arm confirmatory trial of pazopanib in patients with paclitaxelpretreated primary cutaneous angiosarcoma Japan Clinical Oncology Group study JCOG1605 JCOG-PCAS protocol